These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33368395)

  • 1. Screening donors for COVID-19 convalescent plasma.
    Wang HE; Ostrosky-Zeichner L; Katz J; Wanger A; Bai Y; Sridhar S; Patel B
    Transfusion; 2021 Apr; 61(4):1047-1052. PubMed ID: 33368395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
    Dhiman Y; Coshic P; Pandey HC; Khatiwada B; Singh J; Mehta V; Gupta S
    Transfus Med; 2021 Jun; 31(3):149-154. PubMed ID: 33749020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in Establishing a Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Donation Program in a Multicultural Environment.
    Algora M; Mehmood T; Madison DL; AlAmeri J; Abuzakouk M; Tagamtam M; Acena L; Totaan G; Grabski G; Oumeziane N; Rajani P; Taylor L; Guzman J; AbdelWareth LO
    Arch Pathol Lab Med; 2021 Dec; 145(12):1479-1484. PubMed ID: 34407176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
    Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
    Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
    Lasky B; Goodhue Meyer E; Steele WR; Crowder LA; Young PP
    Transfusion; 2021 May; 61(5):1471-1478. PubMed ID: 33458811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
    Terada M; Kutsuna S; Togano T; Saito S; Kinoshita N; Shimanishi Y; Suzuki T; Miyazato Y; Inada M; Nakamoto T; Nomoto H; Ide S; Sato M; Maeda K; Matsunaga A; Satake M; Matsubayashi K; Tsuno H; Kojima M; Kuramistu M; Tezuka K; Ikebe E; Okuma K; Hamaguchi I; Shiratori K; Sato M; Kawakami Y; Inaba K; Igarashi S; Yamauchi R; Matsumura M; Ishimaru K; Zhang B; Kuge C; Ishihara M; Gouda M; Tanaka K; Ishizaka Y; Ohmagari N
    Transfusion; 2021 Jul; 61(7):1998-2007. PubMed ID: 34096059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
    Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
    Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.
    Muttamba W; Lusiba J; Namakula LO; Byakika-Kibwika P; Ssali F; Ddungu H; Mugenyi L; Kiwanuka N; Sekibira R; Kityo C; Keyune D; Acana S; Musinguzi A; Masasi A; Byamugisha J; Mpanju D; Musoki WJ; Tukamuhebwa HA; Nakwagala F; Bagaya BS; Kayongo A; Kimuli I; Nantanda R; Katagira W; Buregyeya E; Byanyima R; Byarugaba B; Siddharthan T; Mwebesa H; Charles O; Joloba ML; Bazeyo W; Kirenga B
    PLoS One; 2021; 16(6):e0252306. PubMed ID: 34138909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
    De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
    Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
    Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
    Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
    Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.
    Reik R; Gammon RR; Carol N; Smith J; Grable M; Forbes S; Wu Y; Reed L; Rogers M; Prichard A; Paul S; Scholl G
    J Clin Apher; 2021 Aug; 36(4):533-546. PubMed ID: 33648025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.
    Ipe TS; Le T; Quinn B; Kellar S; Clark M; Carlisle S; Rassmann A; Hennigan S; Ridenour T; Roberts A; Avery D; Ryan S; Pearson S; Kothari A; Patil N
    Transfusion; 2020 Dec; 60(12):2828-2833. PubMed ID: 32989778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.
    Fazeli A; Sharifi S; Mohammadi S; Bahraini M; Arabkhazaeli A; Jelveh N; Eshghi P
    Transfus Apher Sci; 2022 Apr; 61(2):103302. PubMed ID: 34774440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 convalescent plasma donors: Unique motivations in unique times?
    Crowder LA; Steele WR; Goodhue E; Lasky B; Young PP
    Transfusion; 2023 Apr; 63(4):703-710. PubMed ID: 36866426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study.
    Masser BM; Ferguson E; Thorpe R; Lawrence C; Davison TE; Hoad V; Gosbell IB
    Transfus Med; 2021 Jun; 31(3):176-185. PubMed ID: 33368777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.